The Scientific Committees on Hemostasis, Thrombosis and Vascular Biology and Megakaryocytes and Platelets have developed a session focused on highlighting cutting-edge research being performed by leading investigators in the respective fields. The program will highlight new basic science advances in areas of clinical importance.
Dr. David Lillicrap will discuss the critical role two procoagulant proteins, factor VIII (FVIII) and von Willebrand factor (VWF), play in the hemostatic process. Inherited deficiency states of these proteins result in the bleeding diseases (e.g., hemophilia A and von Willebrand disease), and increased plasma levels of the proteins are significant risk factors for arterial and venous thrombosis. Aspects of the FVIII/VWF interaction will be highlighted with reference to the biology and pathobiology of hemostasis.
Dr. S. Ananth Karumanchi will discuss evidence suggesting that excess soluble fms-like tyrosine kinase1, an endogenous soluble inhibitor of VEGF signaling, may play a causal role in the pathogenesis of preeclampsia. Circulating levels of sFlt1 and placental growth factor PlGF, a ligand for sFlt1 may be used as markers for the early diagnosis of preeclampsia. He will highlight novel treatments such as therapeutic apheresis and RNA interference strategies targeting sFlt1, which are aimed at shifting the balance in favor of pro-angiogenesis and endothelial health for this syndrome.
Dr. Martha Sola-Visner will describe the growing body of evidence suggesting that neonatal megakaryopoiesis is characterized by a developmentally unique dissociation between proliferation, polyploidization and maturation, challenging the paradigm that neonatal megakaryocytes and platelets are simply “immature”. She will discuss the key differences between fetal/neonatal and adult megakaryopoiesis, and their significance in normal development, disease pathogenesis, and response to novel therapies.
The winner of the Mary Rodes Gibson Memorial Award--the trainee with the highest-scoring abstract submitted in the field of hemostasis and thrombosis for the ASH annual meeting--will present their award-winning abstract.